As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices

Novartis said it anticipates an increase of single-digit sales growth in its new medicines. However, Narasimhan also noted that the company will likely have to cut prices on some of its older drugs, particularly as pharmaceuticals are under intense scrutiny in the U.S. over pricing practices. On a conference call with reporters, Narasimhan said he expected Novartis’s net prices to decline by a low-single-digit percentage this year, The Wall Street Journal reported.